Recent HUGE News
- FSD Pharma Announces Filing of Year-End 2022 Results • Business Wire • 04/01/2023 12:00:00 AM
- FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors • Business Wire • 03/30/2023 12:30:00 PM
- FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder • Business Wire • 03/22/2023 12:30:00 PM
- FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activity Of Its Stock • Business Wire • 03/14/2023 12:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Addition of Kevin Harrington, Author, “Shark Tank” Original, and Infomercial Pioneer to its Advisory Board • GlobeNewswire Inc. • 03/01/2023 11:00:00 AM
- Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board • Business Wire • 02/28/2023 01:30:00 PM
- FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2023 Forum • Business Wire • 02/21/2023 07:30:00 AM
- FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements • Business Wire • 02/15/2023 12:30:00 PM
- FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse • Business Wire • 02/14/2023 07:30:00 AM
- InvestmentPitch Media Video Discusses FSD Pharma’s Receipt of No Objection Letter from Health Canada for Clinical Trials for LUCID-21-302 for MS • GlobeNewswire Inc. • 02/09/2023 11:00:00 AM
- FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate • Business Wire • 02/07/2023 01:30:00 PM
- Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) • Business Wire • 01/30/2023 01:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS • GlobeNewswire Inc. • 01/19/2023 11:00:00 AM
- FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation • Business Wire • 01/17/2023 01:30:00 PM
- FSD Pharma Announces Share Repurchase Program • Business Wire • 01/13/2023 01:30:00 PM
- FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia • Business Wire • 01/09/2023 01:30:00 PM
- FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023 • Business Wire • 01/06/2023 01:30:00 PM
- FSD Pharma Announces Changes to the Board of Directors • Business Wire • 11/28/2022 09:30:00 PM
- InvestmentPitch Media Video Discusses FSD Pharma’s Announcement that the Claim for US$30.2 Million Brought by Dr. Raza Bokhari, the Company’s Former CEO, has been Dismissed in its Entirety • GlobeNewswire Inc. • 11/15/2022 11:00:00 AM
- FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari • Business Wire • 11/10/2022 02:00:00 PM
- FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency • Business Wire • 09/29/2022 12:30:00 PM
- FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available • Business Wire • 09/12/2022 12:30:00 PM
- FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome • Business Wire • 09/06/2022 12:30:00 PM
- FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium • Business Wire • 07/13/2022 12:30:00 PM
- FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates • Business Wire • 06/27/2022 12:30:00 PM
ILUS Confirms Further Funding Arrangements and Note Settlement • ILUS • Mar 31, 2023 10:21 AM
Sigyn Therapeutics Announces Filing of 2022 Annual Report on SEC Form 10-K • SIGY • Mar 31, 2023 10:06 AM
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer's Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders Conference • TLSA • Mar 31, 2023 7:07 AM
ARway Secures Multiple New SDK Deals to Drive Growth in $44B Indoor Positioning and Navigation Market • ARWYF • Mar 30, 2023 10:30 AM
Nextech3D.ai Enters Asian Market with Major 3D Modeling Deal to Revolutionize E-Commerce • NTAR • Mar 30, 2023 10:00 AM
OMID Posts 2022 Annual Report and Provides Update • OMID • Mar 30, 2023 9:15 AM